Thiopurines, DNA damage, DNA repair and therapy-related cancer.
about
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agentsEnzymology of purine and pyrimidine antimetabolites used in the treatment of cancerDNA mismatch repair: molecular mechanism, cancer, and ageingAnemia in inflammatory bowel disease: a neglected issue with relevant effectsInsights into open/closed conformations of the catalytically active human guanylate kinase as investigated by small-angle X-ray scattering.Chemical Inhibitors of Non-Homologous End Joining Increase Targeted Construct Integration in Cryptococcus neoformansModel-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients.6-thioguanine: a drug with unrealized potential for cancer therapy.Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 fociPivotal role of inosine triphosphate pyrophosphatase in maintaining genome stability and the prevention of apoptosis in human cells.DNA methyltransferases, DNA damage repair, and cancerHDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of MutSĪ±.Synthesis and quantitative structure-activity relationship of imidazotetrazine prodrugs with activity independent of O6-methylguanine-DNA-methyltransferase, DNA mismatch repair, and p53.Direct observation and quantitative characterization of singlet oxygen in aqueous solution upon UVA excitation of 6-thioguanines.Fusion tyrosine kinase NPM-ALK Deregulates MSH2 and suppresses DNA mismatch repair function novel insights into a potent oncoproteinQuantification of Thiopurine/UVA-Induced Singlet Oxygen ProductionMismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA.A Comparative Analysis of Drug-Induced Hepatotoxicity in Clinically Relevant Situations.Investigations into specificity of azepinomycin for inhibition of guanase: discrimination between the natural heterocyclic inhibitor and its synthetic nucleoside analoguesThiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003.Azathioprine induction of tumors with microsatellite instability: risk evaluation using a mouse model.Effects of 6-thioguanine and S6-methylthioguanine on transcription in vitro and in human cells.Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.Thiopurine Prodrugs Mediate Immunosuppressive Effects by Interfering with Rac1 Protein Function.Nomenclature for alleles of the thiopurine methyltransferase gene.Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.Review and clinical perspectives for the use of infliximab in ulcerative colitis.Mutations at serine 37 in mouse guanylate kinase confer resistance to 6-thioguanine.Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications.Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease.6-thioguanine induces mitochondrial dysfunction and oxidative DNA damage in acute lymphoblastic leukemia cells.Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disordersImplementation of TPMT testing.The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders.Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD.Synthesis of novel thiopurine pyranonucleosides: evaluation of their bioactivity.Diagnosis and treatment of anemia in patients with inflammatory bowel disease.The stress response resolution assay. I. Quantitative assessment of environmental agent/condition effects on cellular stress resolution outcomes in epithelium.Thiopurines induce oxidative stress in T-lymphocytes: a proteomic approach.
P2860
Q24633763-B3FE89E3-F3DF-464A-8C4E-03F36BA9BA6CQ24642847-D0BBC606-3514-4B9D-BA23-ADFDE861E46DQ24647002-B59B024E-D42A-4EDF-BCB9-8A1B14F0BF84Q26822906-492F657B-5C77-4DD6-AA70-B93F3E92587FQ27324073-375D5872-EC44-4BD7-B693-ECCAF82E7692Q28554238-10CBA8B2-58CD-4527-BFE5-42E04EF918B9Q30838395-F472D0DF-5CEB-4733-BE3D-6CE8FA79D929Q33829767-9F38BE0D-4134-4E01-83DD-1E8AC3530063Q34025378-4D51159D-0D37-4E4A-83CF-12167BFB67B3Q34182512-E58101DF-5072-488B-92DC-1C238CBF4D7CQ34298096-6541A42D-5001-4A0A-A18A-876B88FB8AA5Q34301290-334A9A8E-948C-4C8A-A887-C64D81343C7DQ34447471-270E07C4-268C-45B5-BB68-4C780174B85BQ34815465-F9F87B72-CB50-43BA-AE83-B1CD1564681FQ35069957-EA2404B7-12DC-40E7-9962-B47C8DDE1004Q35534821-244C149F-C7BF-4B7E-BA3C-65699094DEB5Q36209738-A9F25EB4-C7E4-44A2-8EEC-6843A5AC847BQ36267296-97968A45-386F-40D0-8043-FD4EA0E4C302Q36374141-BF8D06FB-2CC1-4E10-B19E-D5A85CAC295FQ36393968-B33CA8F3-9495-4422-851F-77736A6A68D3Q36413082-000AF07C-995C-4300-9F25-285C232F515CQ36436001-FBE5AD3E-CE3F-49AE-8FCC-9DC726A05760Q36532537-DCDF6A5F-2A32-46A2-9969-FF41F6BCA337Q36988021-EC8AEE72-47FD-4755-9AEE-E87975D29355Q37034422-55FDBB3C-49AB-4347-BD72-456D93FA3CA7Q37056505-053941CB-C9F9-4996-AC32-0D0475EA97BCQ37087479-4D8DEC19-4485-4496-AF6C-1B030399A0C3Q37114650-59A3FAF5-0E26-4972-80EB-2D1F561466D1Q37136250-DF2DD479-053E-4EDB-A93A-7C1F2F122A4FQ37345896-286C5C4B-E993-4E03-B1CF-2FF390E6DF9DQ37358453-34CD4875-4F66-4A2B-8CEE-67748E5CE2A9Q37389014-29BF9D14-FF91-439E-A61B-56757D71A9BAQ37437248-A874EA9A-AD49-4FD3-90B7-60AAB2DF0A94Q37678056-56536307-E9D5-45F5-80C5-71F0D4EF7D13Q38195146-85953B49-2A39-41E0-8CF7-D109A2696119Q38253832-A8A62616-E59B-4B40-A24F-C4B0D7F29A26Q38899460-B713AEC6-D730-486F-B1A1-58EBF70A11F3Q39044814-5695DAB8-9DCD-4EC0-8B04-0E2E82DDCA10Q39171826-6D4E8FAF-CD47-4A1A-A5EF-E0F6E4F98759Q39242293-77671686-D66F-44B1-9629-8FF6B15EB805
P2860
Thiopurines, DNA damage, DNA repair and therapy-related cancer.
description
2006 nĆ® lÅ«n-bĆ»n
@nan
2006幓ć®č«ę
@ja
2006幓č«ę
@yue
2006幓č«ę
@zh-hant
2006幓č«ę
@zh-hk
2006幓č«ę
@zh-mo
2006幓č«ę
@zh-tw
2006幓č®ŗę
@wuu
2006幓č®ŗę
@zh
2006幓č®ŗę
@zh-cn
name
Thiopurines, DNA damage, DNA repair and therapy-related cancer.
@ast
Thiopurines, DNA damage, DNA repair and therapy-related cancer.
@en
type
label
Thiopurines, DNA damage, DNA repair and therapy-related cancer.
@ast
Thiopurines, DNA damage, DNA repair and therapy-related cancer.
@en
prefLabel
Thiopurines, DNA damage, DNA repair and therapy-related cancer.
@ast
Thiopurines, DNA damage, DNA repair and therapy-related cancer.
@en
P356
P1476
Thiopurines, DNA damage, DNA repair and therapy-related cancer.
@en
P2093
Peter Karran
P304
P356
10.1093/BMB/LDL020
P577
2006-01-01T00:00:00Z